Characterizing mechanisms of sensitivity and resistance to anti-androgen therapy with whole-body molecular imaging.

Predictive and prognostic value of 18F-prostate specific membrane antigen PET-CT and 18F-fluorodihydrotestosterone PET-CT in patients with metastatic castration-resistant prostate cancer treated with androgen biosynthesis inhibitors.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON26005

Enrollment

Registered

2019-07-18

Start date

2019-04-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic castration-resistant prostate cancer

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed prostate cancer adenocarcinoma 2. Eligible for abiraterone treatment as judged by the treating physician. 3. Castrate levels of serum testosterone 4. Progressive disease manifest by either imaging (bone imaging, MRI, CT, or PSMA PET-CT) or biochemical progression (PSA). 5. Visible lesions on CT, bone imaging, MRI, or PSMA PET-CT consistent with disease.

Exclusion criteria

Exclusion criteria: 1. Previous anaphylactic reaction to either FDHT or PSMA.

Design outcomes

Primary

Measure	Time frame
Prognostic value of 18F-PSMA and FDHT imaging in men with mCRPC who will undergo AR-directed therapy.	—

Secondary

Measure	Time frame
Utility of 18F-PSMA and FDHT imaging as response indicator biomarkers for patients with mCRPC undergoing treatment with androgen biosynthesis inhibitors such as abiraterone.	—

Contacts

Public ContactMatthijs Cysouw

Amsterdam UMC, location VUmc

m.cysouw@amsterdamumc.nl+31-020-4444837

Outcome results